In the past, Reed’s, Inc. has been featured in many publications, and today the company announced to its subscribers that it has been appearing in even more publications recently. In USA Today, Reed’s Virgil’s Diet Root Beer was named a “hit”. The root beer isn’t made with any artificial sweeteners, but instead perfectly blended with a number of different herbs and spices. Commenting on the exquisite taste, the article stated, “No question that this particular soda would make the perfect rootbeer float.”

The company also grabbed the attention of WallStreetNewsReporter, who interviewed CEO Christopher Reed. Reed’s, Inc. expects 2008 revenues to exceed last year’s revenues of $13 million by up to 20%. In order to meet increasing demand, the company is streamlining its business operations, refining its target market, and has upped the brewing capacity to handle up to $75 million in annual sales.

The company’s beverages are not the only products getting attention, however,

Taplmmune, Inc. (TPIM.OB) is a developer of new innovative therapeutics and vaccines in the oncology and infectious disease areas. The company’s therapeutics and vaccines are based on technologies that utilize transporters associated with Antigen Processing (TAP). TAP therapy offers improvements in efficacy as well as reduced side effects and a boost in body defenses.

Teplmmune’s TAP cancer vaccine primarily moves antigens to the surface of cells and restores TAP proteins and the immune system’s ability to recognize and destroy cancer cells. The TAP molecule has also shown abilities to enhance the potency of vaccines against infectious diseases.

Taplmmune’s TAP has already been through clinical studies and has proven several forms of cancer that are deficient to the vaccine. Some cancers deficient to the vaccine include melanoma, colon, cervical, lung, prostate, breast and ovarian. The company began their preclinical testing of TAP in 2007, and is currently